SOURCE: Wall Street Equity Research

Wall Street Equity Research

October 13, 2010 08:56 ET

Professional Research on Sanofi-Aventis and VIVUS Inc. -- Healthcare Sector Under Review

JOHANNESBURG, SOUTH AFRICA--(Marketwire - October 13, 2010) -  www.wallstreetequityresearch.com gives shareholders valuable insight on healthcare stocks Sanofi-Aventis (NYSE: SNY) and VIVUS Inc. (NASDAQ: VVUS). Sign up today at www.wallstreetequityresearch.com to receive free research reports on these equities.

With mid-term elections looming, the Obama administration is working to engender political goodwill by revamping some of the tax credits available for several industries. The Biotechnology Sector could see benefit from this as the Obama administration hopes to revamp a research and development tax credit by increasing it from 14% to 17% and making it a permanent fixture. While some within the sector are worried that this credit will only benefit larger more profitable companies, smaller ones could see a trickledown effect as R&D experiences the increasing trend of outsourcing.

www.wallstreetequityresearch.com is a specialized website where investors can have specific access to free reports healthcare industry; traders looking for analyst opinions on Sanofi-Aventis, VIVUS Inc. and other companies in this industry are welcomed to sign up for a free one year membership at http://www.wallstreetequityresearch.com/.

Outsourcing research and development is a growing trend within the Biotechnology sector for several reasons. The primary one is the attempt of companies to streamline their operations in anticipation of the patent falloff coming in 2013. Companies are also trimming their workforces and exploring mergers and acquisitions as a way to supplement their pipelines and increase efficiency. Visit us at http://www.wallstreetequityresearch.com/ to understand the catalysts and forces driving or affecting the healthcare industry in today's economic environment.

The amount of companies in the biotechnology sector has decreased by 25% during the past few years due to weak cash positions and the inability to raise capital beyond one year of operations. While the number of companies with less than a year's worth of capital has decreased to 25%, the amount of struggling companies remains high and creates a volatile market for mergers and acquisitions. At some point the M&A have become very aggressive in nature as hostile bids continue to be a trend in the biotech industry of late. Latest in the list is the hostile $18.5 billion offer Sanofi-Aventis made for Genzyme. Traders can get direct and free access to today's full report on Sanofi-Aventis by signing up at http://wallstreetequityresearch.com/October132010Sanofi-Aventis(SNY)131010.php.

With the earnings season for the Q3 of 2010 in full swing, Sanofi-Aventis will be posting its results on October 28th, whilst another player in the healthcare sphere VIVUS Inc. will releasing its earnings on November 1st. Traders can have complimentary access to today's complete research report on VIVUS Inc. by signing up at http://wallstreetequityresearch.com/October132010VIVUSInc.(VVUS)131010.php

About Wall Street Equity Research: 

Wall Street Equity Research looks to bring simplicity and highly sophisticated research to an ever-changing investing environment. Wall Street Equity Research has been partnering with a number of North American and Emerging Economies analysts to bring you the best of both continents in terms of market analysis and analytical opinions. 

Contact Information